» Articles » PMID: 6141560

Inhibition of Growth of Pancreatic Carcinomas in Animal Models by Analogs of Hypothalamic Hormones

Overview
Specialty Science
Date 1984 Jan 1
PMID 6141560
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Using animal models of acinar and ductal pancreatic cancer, we investigated the effect of analogs of hypothalamic hormones on tumor growth. In Wistar/Lewis rats bearing the acinar pancreatic tumor DNCP-322, chronic administration of [L-5-Br-Trp8]somatostatin-14 significantly decreased tumor weights and volume. Somatostatin-28 and the cyclic hexapeptide analog of somatostatin cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe) failed to influence the growth of this tumor. The agonistic analog of luteinizing hormone-releasing hormone [D-Trp6]LH-RH also significantly decreased tumor weight and volume in this model and reduced testosterone levels and the weights of the ventral prostate and tests. In Syrian hamsters bearing ductal type of pancreatic carcinoma, chronic administration of [L-5-Br-Trp8]somatostatin diminished tumor weights and volume. The percentage change in tumor volume was significantly decreased when compared to control animals. In one experiment, cyclic hexapeptide of somatostatin also inhibited growth of this tumor. [D-Trp6]LH-RH, given twice daily or injected in the form of microcapsules for constant controlled release, significantly decreased tumor weight and volume and suppressed serum testosterone levels. Hamsters castrated 4 days after transplantation of the pancreatic tumors showed a significant decrease in weight and volume of these tumors. This suggests that pancreatic cancers may, at least in part, be sex hormone sensitive. [D-Trp6]LH-RH may decrease the growth of pancreatic carcinomas by suppressing androgens. Somatostatin analogs reduce the growth of pancreatic ductal and acinar cancers, probably by inhibiting the release or stimulatory action of gastrointestinal hormones on tumor cells (or both). Inhibition of animal models of pancreatic tumors by chronic administration of somatostatin analogs and [D-Trp6]LH-RH suggests that these compounds should be considered for the development of a new hormonal therapy for cancer of the pancreas.

Citing Articles

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.

Viegas C, Patricio A, Prata J, Fonseca L, Macedo A, Duarte S Pharmaceutics. 2023; 15(9).

PMID: 37765331 PMC: 10536303. DOI: 10.3390/pharmaceutics15092363.


Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.

Mahipal A, Tella S, Kommalapati A, Goyal G, Soares H, Neuger A Invest New Drugs. 2018; 37(3):473-481.

PMID: 30298303 PMC: 7771270. DOI: 10.1007/s10637-018-0676-8.


Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications.

Stengel A, Tache Y Front Endocrinol (Lausanne). 2013; 3:178.

PMID: 23335913 PMC: 3542632. DOI: 10.3389/fendo.2012.00178.


Somatostatin, somatostatin receptors, and pancreatic cancer.

Li M, Fisher W, Kim H, Wang X, Brunicardi C, Chen C World J Surg. 2005; 29(3):293-6.

PMID: 15706439 DOI: 10.1007/s00268-004-7814-5.


Androgen receptor-blocking agents: potential role in pancreatic cancer.

Greenway B Drugs Aging. 2000; 17(3):161-3.

PMID: 11043816 DOI: 10.2165/00002512-200017030-00001.


References
1.
Mortimer C, Tunbridge W, Carr D, Yeomans L, Lind T, Coy D . Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974; 1(7860):697-701. DOI: 10.1016/s0140-6736(74)92903-1. View

2.
de Quijada M, Redding T, Coy D, Torres-Aleman I, Schally A . Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci U S A. 1983; 80(11):3485-8. PMC: 394069. DOI: 10.1073/pnas.80.11.3485. View

3.
Polak J, Pearse A, Grimelius L, Bloom S . Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet. 1975; 1(7918):1220-2. DOI: 10.1016/s0140-6736(75)92198-4. View

4.
Boden G, Sivitz M, Owen O, LANDOR J . Somatostatin suppresses secretin and pancreatic exocrine secretion. Science. 1975; 190(4210):163-5. DOI: 10.1126/science.1166308. View

5.
Coy D, Coy E, Schally A . Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem. 1976; 19(3):423-5. DOI: 10.1021/jm00225a018. View